[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 50 of about 50
1. Pan ZQ, Fang ZQ, Lu WL, Liang C, Wu ZH, Liu XM, Hou L, Zhang H, Zhuo SY, Liao MJ, Gao BF: [Differentially expressed genes in adrenal gland of H22 liver cancer mice with different syndromes and in different stages]. Zhong Xi Yi Jie He Xue Bao; 2008 Aug;6(8):843-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differentially expressed genes in adrenal gland of H22 liver cancer mice with different syndromes and in different stages].
  • OBJECTIVE: To reveal the characteristics of gene expression in adrenal gland of H22 tumor mice with typical syndromes and in different liver cancer stages.
  • METHODS: By the quantitative four diagnosis and syndrome differentiation methods and GeneChip Mouse Exon 1.0 ST Array, we observed adrenal gland gene expression in H22 tumor mice with pathogenic factor-toxin predominance syndrome and qi deficiency syndrome in the earlier stage, yang-qi deficiency syndrome in the intermediate stage, and qi-yin-yang deficiency syndrome in the advanced stage.
  • CONCLUSION: With the development of the tumorigenesis, the symptoms and signs and differentially expressed genes in adrenal gland of H22 tumor mice can be measured.
  • Up-regulated and down-regulated coincident genes may be the features of H22 tumor mice different from those of normal mice.
  • [MeSH-major] Adrenal Glands / metabolism. Diagnosis, Differential. Gene Expression Profiling. Liver Neoplasms, Experimental / genetics. Medicine, Chinese Traditional


2. Fenske W, Völker HU, Adam P, Hahner S, Johanssen S, Wortmann S, Schmidt M, Morcos M, Müller-Hermelink HK, Allolio B, Fassnacht M: Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer; 2009 Sep;16(3):919-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma.
  • Owing to the rarity of adrenocortical carcinoma (ACC) no prognostic markers have been established beyond stage and resection status.
  • Accelerated glycolysis is a characteristic feature of cancer cells and in a variety of tumour entities key factors in glucose metabolism like glucose transporter 1 and 3 (GLUT1 and -3), transketolase like-1 enzyme (TKTL1) and pyruvate kinase type M2 (M2-PK) are overexpressed and of prognostic value.
  • Immunohistochemical analysis was performed on tissue microarrays of paraffin-embedded tissue samples from 167 ACCs, 15 adrenal adenomas and 4 normal adrenal glands.
  • In conclusion, GLUT1 is a highly promising stage-independent, prognostic marker in ACC.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / metabolism. Glucose Transporter Type 1 / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Biomarkers, Tumor / physiology. Female. Glucose / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465749.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; IY9XDZ35W2 / Glucose
  •  go-up   go-down


3. Casey EM, Harb W, Bradford D, Bufill J, Nattam S, Patel J, Fisher W, Latz JE, Li X, Wu J, Hanna N: Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. J Thorac Oncol; 2010 Nov;5(11):1815-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
  • INTRODUCTION: : Bevacizumab is approved in combination with chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC).
  • METHODS: : ELIGIBILITY CRITERIA: ≥18 years of age, chemonaïve, stage IIIB/IV nonsquamous NSCLC, and Eastern Cooperative Oncology Group performance status 0 to 1.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adrenal Gland Neoplasms / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Double-Blind Method. Female. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Indoles / administration & dosage. Male. Middle Aged. Neoplasm Staging. Pemetrexed. Placebos. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881647.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Glutamates; 0 / Indoles; 0 / Placebos; 04Q9AIZ7NO / Pemetrexed; 2S9ZZM9Q9V / Bevacizumab; 5Z93L87A1R / Guanine; BG3F62OND5 / Carboplatin; UC96G28EQF / enzastaurin
  •  go-up   go-down


Advertisement
4. Ng VW, Ma RC, So WY, Choi KC, Kong AP, Cockram CS, Chow CC: Evaluation of functional and malignant adrenal incidentalomas. Arch Intern Med; 2010 Dec 13;170(22):2017-20
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of functional and malignant adrenal incidentalomas.
  • BACKGROUND: Adrenal incidentalomas are adrenal masses discovered inadvertently.
  • We undertook this study to review the clinical characteristics of patients with adrenal incidentalomas who presented to a tertiary endocrine center in Hong Kong.
  • METHODS: Retrospective review of all 139 cases of adrenal incidentalomas that were referred to the Endocrine Centre of the Prince of Wales Hospital between June 1, 2000, and May 31, 2007.
  • We reviewed detailed patient history, physical examination findings, and symptoms and signs related to hormonal hypersecretion or malignant neoplasm and recorded clinical indications for performing diagnostic radiological imaging.
  • RESULTS: Sixty-one patients (43.9%) had nonfunctional benign adrenal adenomas, 52 (37.4%) had functional lesions, 15 (10.8%) had malignant adrenal lesions, and the remaining 11 (7.9%) had varying adrenal disease.
  • Only 5 of the 27 patients with cortisol-secreting adrenal incidentalomas had symptoms or signs of excess cortisol levels at presentation.
  • CONCLUSIONS: Adrenal incidentaloma is a commonly encountered clinical problem.
  • Functional or primary malignant adrenal incidentalomas can be detected at an earlier stage during hormonal and radiological evaluations, which provides an opportunity for further management.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Aldosterone / secretion. Catecholamines / secretion. Hydrocortisone / secretion
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Corticotropin-Releasing Hormone / blood. Early Detection of Cancer. Female. Hong Kong / epidemiology. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21149760.001).
  • [ISSN] 1538-3679
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catecholamines; 4964P6T9RB / Aldosterone; 9015-71-8 / Corticotropin-Releasing Hormone; WI4X0X7BPJ / Hydrocortisone; Adrenal incidentaloma
  •  go-up   go-down


5. Russo P, Synder M, Vickers A, Kondagunta V, Motzer R: Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. ScientificWorldJournal; 2007;7:768-78
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer.
  • Between July 1989 and September 2003, we queried our department's renal tumor database for patients undergoing cytoreductive nephrectomy alone or in conjunction with complete metastasectomy.
  • Clinical and pathological factors analyzed included primary tumor size, stage and histological subtype, age, gender, Karnofsky Performance Status (KPS) prior to nephrectomy, number and location of metastatic sites, and the presence or absence of any systemic therapy.
  • Sixty-four percent of patients had a single site of metastatic disease, with lung the most common, followed by bone, adrenal, brain, and liver.
  • For patients with metastatic renal cell carcinoma, surgical resection of the primary tumor alone (cytoreductive nephrectomy) or in conjunction with metastasectomy can be accomplished with acceptable perioperative morbidity and mortality.
  • This surgical experience provides a contemporary foundation as new targeted therapeutic agents are integrated into the neoadjuvant or adjuvant treatment of locally advanced and metastatic renal cancer.
  • [MeSH-major] Kidney Neoplasms / mortality. Kidney Neoplasms / surgery. Neoplasm Metastasis / prevention & control. Nephrectomy / mortality. Risk Assessment / methods


6. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B, German Adrenocortical Carcinoma Registry Group, European Network for the Study of Adrenal Tumors: Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer; 2009 Jan 15;115(2):243-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare malignancy, and it was only in 2004 that the International Union Against Cancer (UICC) defined TNM criteria and published the first staging classification.
  • METHODS: The German ACC Registry comprising 492 patients was searched for patients who were diagnosed between 1986 and 2007 with detailed information on primary diagnosis and a minimum follow-up of 6 months.
  • Patients were assigned to UICC tumor stage, and disease-specific survival (DSS) was assessed.
  • RESULTS: In total, 416 patients with a mean follow-up of 36 months met the inclusion criteria (stage I, n=23 patients; stage II, n=176 patients; stage III, n=67 patients; stage IV, n=150 patients).
  • Kaplan-Meier analysis revealed a stage-dependent DSS.
  • However, DSS in patients with stage II ACC did not differ significantly from DSS in patients with stage III ACC (hazard ratio, 1.38; 95% confidence interval, 0.89-2.16).
  • Furthermore, patients who had stage IV ACC without distant metastases had an improved DSS compared with patients who had metastatic disease (P=.004).
  • An analysis of different potential risk factors for defining stage III ACC revealed important roles in DSS for tumor infiltration in surrounding tissue, venous tumor thrombus (VTT), and positive lymph nodes; whereas tumor invasion in adjacent organs carried a prognosis similar to that of infiltration in surrounding tissue only.
  • On the basis of the current analysis, a revised classification with superior prognostic accuracy is proposed (the European Network for the Study of Adrenal Tumors classification).
  • In this system, stage III ACC is defined by the presence of positive lymph nodes, infiltration of surrounding tissue, or VTT; and stage IV ACC is restricted to patients with distant metastasis.
  • [MeSH-major] Adrenocortical Carcinoma / pathology. Neoplasm Staging / classification
  • [MeSH-minor] Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • [CommentIn] Cancer. 2009 Dec 15;115(24):5847; author reply 5848 [19827149.001]
  • (PMID = 19025987.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Allolio B; Behrend M; Bucsky P; Brauckhoff M; Fasanacht M; Fottner C; Haaf M; Hahner S; Johanssen S; Koschker AC; Langer P; Laubner K; Linden T; Maeder U; Morcos M; Oelkers W; Quinkler M; Reincke M; Reisch N; Saeger W; Weismann D; Willenberg HS; Wortmann S; Baudin E; Bertherat J; Beuschlein F; Mannelli M; Terzolo M
  •  go-up   go-down


7. Ahlborn GJ, Nelson GM, Grindstaff RD, Waalkes MP, Diwan BA, Allen JW, Kitchin KT, Preston RJ, Hernandez-Zavala A, Adair B, Thomas DJ, Delker DA: Impact of life stage and duration of exposure on arsenic-induced proliferative lesions and neoplasia in C3H mice. Toxicology; 2009 Aug 3;262(2):106-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of life stage and duration of exposure on arsenic-induced proliferative lesions and neoplasia in C3H mice.
  • Epidemiological studies suggest that chronic exposure to inorganic arsenic is associated with cancer of the skin, urinary bladder and lung as well as the kidney and liver.
  • To further characterize age susceptibility to arsenic carcinogenesis we administered 85 ppm inorganic arsenic in drinking water to C3H mice during gestation, prior to pubescence and post-pubescence to compare proliferative lesion and tumor outcomes over a one-year exposure period.
  • In contrast, inorganic arsenic significantly decreased the incidence of tumors in liver (0%) and adrenal glands (0%) of male mice continuously exposed from gestation through one year, as compared to levels in control (30 and 65%, respectively) and gestation only (33 and 55%, respectively) exposed mice.
  • Together, these results suggest that continuous inorganic arsenic exposure at 85 ppm from gestation through one year increases the incidence and severity of urogenital proliferative lesions in female mice and decreases the incidence of liver and adrenal tumors in male mice.
  • [MeSH-major] Adrenal Gland Neoplasms / chemically induced. Arsenites / toxicity. Carcinogens / toxicity. Liver Neoplasms / chemically induced. Oviducts / drug effects. Sodium Compounds / toxicity. Urinary Bladder / drug effects

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):920-8 [17565158.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1293-6 [16882542.001]
  • [Cites] Environ Health Perspect. 2007 Oct;115(10):1503-9 [17938743.001]
  • [Cites] PLoS Genet. 2007 Nov;3(11):e207 [18039032.001]
  • [Cites] J Lipid Res. 1999 Sep;40(9):1549-58 [10484602.001]
  • [Cites] Jpn J Cancer Res. 2000 Jun;91(6):579-81 [10874208.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(3):281-6 [10983894.001]
  • [Cites] Epidemiology. 2000 Nov;11(6):673-9 [11055628.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):249-61 [11312654.001]
  • [Cites] Rev Environ Contam Toxicol. 2001;169:165-214 [11330077.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1387-97 [12151359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11482-6 [12177411.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1933-6 [12419843.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Epidemiology. 2003 Mar;14(2):174-82 [12606883.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):37-65 [14643412.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):377-84 [15276417.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):394-404 [15276419.001]
  • [Cites] Environ Health Perspect. 1976 Dec;18:133-9 [1030391.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7677-81 [2174729.001]
  • [Cites] Am J Epidemiol. 1992 Mar 1;135(5):462-76 [1570813.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1296-300 [7882325.001]
  • [Cites] Am J Epidemiol. 1995 Mar 15;141(6):523-30 [7900719.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):209-18 [9219559.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):561-9 [9758107.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1873-6 [10469637.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;84:269-477 [15645578.001]
  • [Cites] Cancer Lett. 2005 Jun 1;223(1):27-35 [15890234.001]
  • [Cites] Toxicol Lett. 2005 Aug 14;158(2):87-94 [16039397.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Oct 15;208(2):186-97 [16183392.001]
  • [Cites] J Agric Food Chem. 2005 Nov 2;53(22):8813-9 [16248589.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2179-86 [16014701.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1337-45 [16452187.001]
  • [Cites] Toxicology. 2006 Jun 1;223(1-2):82-100 [16677751.001]
  • [Cites] Crit Rev Toxicol. 2006 Feb;36(2):99-133 [16736939.001]
  • [Cites] Toxicology. 2006 Jul 5;224(1-2):147-55 [16753250.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):675-81 [16827809.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Aug 1;222(3):281-8 [17118416.001]
  • (PMID = 19450653.001).
  • [ISSN] 1879-3185
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC005488-22; United States / Intramural NIH HHS / / Z01 BC005488-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Arsenites; 0 / Carcinogens; 0 / Sodium Compounds; 48OVY2OC72 / sodium arsenite
  • [Other-IDs] NLM/ NIHMS127111; NLM/ PMC3496158
  •  go-up   go-down


8. Miyazaki T, Tagawa T, Nakamura A, Yamasaki N, Hashizume S, Matsumoto K, Taguchi T, Morino S, Nagayasu T: [Surgical treatment for stage IV lung cancer]. Kyobu Geka; 2006 Jan;59(1):36-40
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for stage IV lung cancer].
  • OBJECTIVE: To find out the optimal surgical indication in stage IV lung cancer patients, we evaluated them retrospectively.
  • The metastatic lesions were lung (33.9%), brain (24.2%), liver, bone, adrenal gland and so on.
  • The overall survival rate of stage IV lung cancer was 10.4% at 5-year.
  • Two were lung and the others were brain and adrenal gland metastasis without lymph node metastasis.
  • CONCLUSION: Stage IV lung cancer with lung or brain or adrenal gland metastasis without lymph node metastasis should be resected.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging / mortality. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440683.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Porpiglia F, Fiori C, Daffara F, Zaggia B, Bollito E, Volante M, Berruti A, Terzolo M: Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol; 2010 May;57(5):873-8
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer.
  • BACKGROUND: Although there is consensus that laparoscopy is the standard of care for the resection of benign adrenal tumours, there is controversy regarding the role of laparoscopy for the resection of adrenocortical cancer (ACC).
  • OBJECTIVE: The aim of the present study was to review the ACC database of the San Luigi Hospital to compare the oncologic effectiveness of open adrenalectomy (OA) versus laparoscopic adrenalectomy (LA) in the treatment of patients with stage I and II ACC.
  • DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective analysis involving 43 patients with stage I and II ACC who had undergone radical surgery.
  • CONCLUSIONS: The present findings provide interesting evidence that OA and LA may be comparable in terms of recurrence-free survival for patients with stage I and II ACC when the principles of surgical oncology are respected.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20137850.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


10. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F, Karakiewicz PI: The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer; 2010 Mar;46(4):713-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.
  • BACKGROUND: A reclassification of the International Union Against Cancer (UICC) staging system for adrenocortical carcinoma (ACC) patients has recently been proposed by the European Network for the Study of Adrenal Tumors (ENSAT) to better discriminate between cancer-specific mortality (CSM) risk strata.
  • Conversely, a statistically significant difference was observed between 2008 ENSAT stage II and stage III patients (p<0.001).
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Neoplasm Staging / standards

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20044246.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


11. Siemer S, Lehmann J, Loch A, Becker F, Stein U, Schneider G, Ziegler M, Stöckle M: Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol; 2005 Jan;173(1):33-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current TNM classification of renal cell carcinoma evaluated: revising stage T3a.
  • PURPOSE: : Recent studies of rare cases of pT3a renal cell carcinoma extending directly into the adrenal gland showed worse survival than in other pT3a cases and recategorization as stage pT4 was suggested.
  • We assessed the prognostic validity of a stage pT3a diagnosis based on perirenal fat infiltration.
  • Focusing on pT3a tumors, as defined by perirenal fat infiltration, numerous clinical and histopathological parameters were investigated by univariate and multivariate statistical methods with cancer specific survival as the primary end point.
  • In patients with pT3a tumors tumor size was a significant parameter predicting survival.
  • The most significant cutoff value for tumor size in pT3a disease was 7 cm.
  • Therefore, to assess the prognostic value of the current T classification in regard to T3a tumors we excluded patients with tumor stage cM+ for further subgroup analysis.
  • After splitting pT3a into a modified T1/T2 classification a significant difference in 5-year survival analysis for a modified T1/T2 stage was found (pT1 plus pT3a less than 7 cm 90% vs pT2 plus pT3a greater than 7 cm 73%, p <0.001).
  • Subsequently multivariate analysis in all 1,794 patients showed that modified T stage was an independent significant predictor of cancer specific survival.
  • Tumors directly infiltrating the adrenal gland should be reclassified as T4.
  • [MeSH-minor] Humans. Neoplasm Invasiveness. Neoplasm Staging. Nephrectomy. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592020.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kasperlik-Zaluska AA, Cichocki A: Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up. J Exp Ther Oncol; 2005;5(2):125-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
  • Metastatic or regional stage was diagnosed in 15 patients, while localized disease in three patients.
  • In the group of patients with regional or metastatic stage, both the o,p'-DDE levels and the o,p'-DDE/o,p'-DDD ratios were higher in the survivors than in non-survivors.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents, Hormonal / blood. Mitotane / analogs & derivatives. Mitotane / blood

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471038.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 34113-46-7 / 2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid; 3424-82-6 / 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene; 78E4J5IB5J / Mitotane
  •  go-up   go-down


13. Zhang W, Dahlberg SE, Yang D, Sandler AB, Brahmer JR, Schiller JH, Carbone DP, Johnson DH, Lenz H: Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol; 2009 May 20;27(15_suppl):8032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have shown certain germline polymorphisms (SNPs) are associated with clinical outcome in advanced breast cancer pts treated with paclitaxel plus bev and in advanced colorectal cancer pts treated with first line 5-FU or capecitabine in combination with oxaliplatin and bev.
  • Multivariable Cox models adjusted for gender, PS, stage, adrenal, liver and bone mets were separately fitted for each SNP to obtain estimates of hazard ratios.
  • Pts with mutant homozygote CC genotype for ICAM1 T469C had significantly higher tumor response rate (39%) than heterozygote CT (13%) and homozygote TT (20%) genotype (Fisher's test, p=0.04).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962832.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, Lee JE: Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol; 2010 Jan;17(1):263-70
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
  • Factors predicting increased risk of recurrence on multivariate analysis were surgery at an outside institution [hazard ratio (HR) 2.56, 95% confidence interval (CI) 1.44-4.53, P = 0.001] and no treatment with adjuvant mitotane (HR 1.95, 95% CI 1.06-3.59, P = 0.03), and those predicting a poorer survival were advanced stage at presentation (P = 0.01) and surgery at an outside institution (HR 2.62, 95% CI 1.31-5.25, P = 0.007).
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851811.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


15. Debevec L, Erzen J, Debeljak A, Crnjac A, Kovac V: Exploratory thoracotomy and its influence on the survival of patients with lung cancer. Wien Klin Wochenschr; 2006 Aug;118(15-16):479-84
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploratory thoracotomy and its influence on the survival of patients with lung cancer.
  • PURPOSE: To evaluate diagnostic procedures, reasons for exploratory thoracotomy (ET), causes of unresectability of lung cancer, possibility for reducing numbers of ETs, and the influence of ET on survival.
  • PATIENTS AND METHODS: Between 1990 and 1999, 1808 patients with lung cancer were operated on.
  • The clinical stages were: three patients in stage IA, 28 in IB, one in IIA, 35 in IIB, 50 in IIIA, 10 in IIIB (all due to invasion of the mediastinum), and four patients in IV (three with ipsilateral pulmonary and one with solitary suprarenal metastasis).
  • The control group for calculating survival difference consisted of 130 consecutive non-operated patients with comparable characteristics (age, sex, clinical stage, performance status, histology and comorbidity) who were diagnosed during the period 1996-1998.
  • Clinical and surgical staging were equal in 3% of stage IIB patients, in 24% of stage IIIA, 100% of stage IIIB and 75% of patients in stage IV.
  • The reasons for ET were: diagnosis of preoperatively unverified tumor in one patient, necessity for pneumonectomy in the case of poor pulmonary function in 11 patients, and unresectability in 119 (due to invasion of the mediastinum in 98 patients, thoracic wall in three and vertebral body in one, and due to pleural metastases in 17 patients).
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiography, Thoracic. Survival Analysis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957979.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


16. Kuczyk M, Wegener G, Jonas U: The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol; 2005 Aug;48(2):252-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer.
  • INTRODUCTION: Solitary adrenal metastases occur in about 1.2-10% of renal cell cancer patients.
  • Since the vast majority of intraadrenal lesions can be detected preoperatively, we and others have recently recommended to renounce a routine adrenalectomy during surgery of renal cell cancer.
  • However, the impact of adrenalectomy on the patients' clinical prognosis in case of a solitary metastatic lesion within the adrenal gland remains an issue of controversial discussion.
  • PATIENTS AND METHOD: Between 1981 and 2000, 648 patients (440 males and 208 females) underwent nephrectomy in combination with adrenalectomy in our clinic for the diagnosis of renal cell cancer.
  • The median age at first diagnosis was 59 (range 33-84) and 60 (range 20-85) years for male and female patients, respectively.
  • According to the TNM - classification system (2003) tumor stages were classified as follows: T1, 228 pat. (37%); T2, 70 pat. (11%); T3, 287 pat. (46%); T4, 37 pat. (6%).
  • Although metastases of the adrenal gland were diagnosed in 48 patients, solitary intraadrenal metastases without further systemic spread were observed in only 13 cases.
  • Several patients' and tumor characteristics (age, tumor stage and size, the presence of regional lymph node metastases, the presence of metastatic lesions at different organ sites as well as the detection of solitary intraadrenal metastases) were correlated with the patients' overall survival by univariate and multivariate statistical analysis (logistic Cox regression analysis).
  • The observation that the long - term survival of the latter patients is comparable to that of patients with organ - confined disease might suggest the establishment of a separate TNM - category for patients revealing a solitary metastasis within the adrenal gland and no hint at further systemic metastatic spread.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Adrenalectomy. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology


17. Nuver J, Smit AJ, Wolffenbuttel BH, Sluiter WJ, Hoekstra HJ, Sleijfer DT, Gietema JA: The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol; 2005 Jun 1;23(16):3718-25
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.
  • PURPOSE: The metabolic syndrome may be an important risk factor for cardiovascular disease in long-term survivors of testicular cancer (TC).
  • PATIENTS AND METHODS: We included TC patients cured by orchidectomy and cisplatin-based chemotherapy, stage I TC patients after orchidectomy only, and healthy men of comparable age.
  • RESULTS: Eighty-six chemotherapy patients (median follow-up, 7 years) were compared with 44 stage I patients and 47 controls.
  • Adrenal and thyroid hormone production were unaffected.
  • CONCLUSION: We found gonadal dysfunction, but normal adrenal and thyroid function.

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Jun 1;23(16):3663-5 [15738543.001]
  • (PMID = 15738540.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sex Hormone-Binding Globulin; 3XMK78S47O / Testosterone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


18. Balogova S, Huchet V, Kerrou K, Nataf V, Gutman F, Antoine M, Ruppert AM, Prignon A, Lavolée A, Montravers F, Mayaud C, Cadranel J, Talbot JN: Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nucl Med Commun; 2010 May;31(5):389-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose.
  • AIM: Bronchioloalveolar (BAC) cancer is a source of false-negative F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) results.
  • We carried out this prospective pilot study to evaluate whether FCH PET/CT could detect lung cancer with a BAC component and could be more sensitive than FDG in this aim.
  • RESULTS: Nine patients (12 lesions) presented BAC or adenocarcinoma with BAC features, two patients presented adenocarcinoma without BAC features (five lesions) and four patients presented benign lesions (15 non-malignant sites).
  • For both FCH and FDG, patient-based sensitivity was 78% for detecting cancer with a BAC component and 82% for detecting malignancy.
  • Site-based sensitivity for detecting malignancy was 76 and 75% for detecting cancer with BAC features, for both radiopharmaceuticals.
  • In these early-stage cancers, only one adrenal metastasis was observed that took up FCH and FDG.
  • CONCLUSION: In this population of patients with ground-glass opacities selected on CT suggestive of BAC or with a history of BAC and a recent lung anomaly on CT, FCH detected all malignant lesions with at least a 2.0 cm short axis.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145579.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / fluorocholine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; N91BDP6H0X / Choline
  •  go-up   go-down


19. Li J, Ma S, Kang S, Xie J, Sheng X, Luo R: [Evaluation on survival in locally advanced non-small cell lung cancer (NSCLC) for multimodality treatment with or without operation]. Zhongguo Fei Ai Za Zhi; 2005 Dec 20;8(6):535-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation on survival in locally advanced non-small cell lung cancer (NSCLC) for multimodality treatment with or without operation].
  • BACKGROUND: It is uncertain that the effect of multimodality treatment with operation on survival for locally advanced non-small cell lung cancer (NSCLC).
  • Arm A (n=56): 39 cases were at stage IIIA, and 17 at stage IIIB; Median KPS was 80 (range from 70 to 90 ); Multimodality treatment program included operation, chemotherapy, radiotherapy and traditional Chinese herb medicine.
  • Arm B (n=58): 23 cases were at stage IIIA, and 35 at stage IIIB; Median KPS was 70 (range from 60 to 90); Treatment program was the same approximately as arm A except for no operation.
  • (1) Metastatic locations in follow-up, in turn, showed as: lymph node, pleural-lung, bone, brain, liver, pericardium, skin and adrenal;.
  • (1) Metastatic locations in follow-up, in turn, showed as: lymph node, pleural-lung, bone, brain, liver, pericardium, skin, adrenal, pancreatic and esophageal metastasis;.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21208544.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol; 2009 Aug 10;27(23):3742-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
  • PURPOSE: It has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent.
  • PATIENTS AND METHODS: This was a phase I/II study of abiraterone acetate in castrate, chemotherapy-naive CRPC patients (n = 54) with phase II expansion at 1,000 mg (n = 42) using a two-stage design to reject the null hypothesis if more than seven patients had a prostate-specific antigen (PSA) decline of > or = 50% (null hypothesis = 0.1; alternative hypothesis = 0.3; alpha = .05; beta = .14).
  • Computed tomography scans every 12 weeks and circulating tumor cell (CTC) enumeration were performed.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Apr 29;355(9214):1491-8 [10801170.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):27-33 [18695026.001]
  • [Cites] Cytometry. 2002 Apr 1;47(4):248-55 [11933015.001]
  • [Cites] CA Cancer J Clin. 2002 May-Jun;52(3):154-79 [12018929.001]
  • [Cites] J Urol. 2002 Aug;168(2):542-5 [12131305.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2673-8 [12860943.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):440-8 [14760063.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1025-33 [15020604.001]
  • [Cites] Eur Urol. 2004 May;45(5):581-4; discussion 585 [15082199.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2317-25 [15150570.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6897-904 [15501967.001]
  • [Cites] Clin Invest Med. 1982;5(4):267-75 [6819101.001]
  • [Cites] J Steroid Biochem. 1988 Nov;31(5):845-52 [2462135.001]
  • [Cites] Anticancer Drug Des. 1988 Dec;3(3):185-90 [3264700.001]
  • [Cites] J Steroid Biochem. 1989 Dec;33(6):1191-5 [2559252.001]
  • [Cites] J Med Chem. 1990 Sep;33(9):2452-5 [2391687.001]
  • [Cites] J Med Chem. 1990 Nov;33(11):3050-5 [2231604.001]
  • [Cites] Stat Med. 1992 May;11(7):853-62 [1604065.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Dec 1;75(1):1-10 [11179903.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1440-50 [10735891.001]
  • [Cites] J Steroid Biochem Mol Biol. 1994 Sep;50(5-6):267-73 [7918112.001]
  • [Cites] J Med Chem. 1995 Jun 23;38(13):2463-71 [7608911.001]
  • [Cites] J Urol. 1997 Apr;157(4):1204-7 [9120902.001]
  • [Cites] J Urol. 2005 Mar;173(3):790-6 [15711271.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1241-6 [16287438.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):516-21 [16622120.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):257-62 [17235043.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2030-7 [17404083.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7053-8 [18056182.001]
  • [Cites] BJU Int. 2008 Feb;101(4):440-3 [17941935.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1148-59 [18309951.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4447-54 [18519708.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6407-15 [18676866.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4563-71 [18645193.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6302-9 [18829513.001]
  • [CommentIn] Eur Urol. 2009 Oct;56(4):744-5 [19995526.001]
  • (PMID = 19470933.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / A7851; United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / / C51/A7401; United Kingdom / Medical Research Council / / G0501019
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Androgen Antagonists; 0 / Androstenes; 0 / Androstenols; 0 / Antineoplastic Agents, Hormonal; 0 / Enzyme Inhibitors; 3XMK78S47O / Testosterone; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase; EC 3.4.21.77 / Prostate-Specific Antigen; G819A456D0 / abiraterone
  • [Other-IDs] NLM/ EMS28710; NLM/ PMC3535569
  •  go-up   go-down


21. Eloubeidi MA, Cerfolio RJ, Chen VK, Desmond R, Syed S, Ojha B: Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg; 2005 Jan;79(1):263-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided fine needle aspiration of mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans.
  • BACKGROUND: The treatment of patients with non-small cell lung cancer (NSCLC) depends on the stage.
  • The reference standard included thoracotomy with complete lymphadenectomy in patients with lung cancer or if EUS-FNA was benign, repeat clinical imaging, or long-term follow-up.
  • RESULTS: There were 104 patients (63 men) with 125 lesions (117 lymph nodes, 8 left adrenal glands) who underwent EUS-FNA.
  • EUS-FNA was more accurate and had a higher positive predictive value than the PET or CT (p < 0.001) scan in confirming cancer in the posterior mediastinal lymph nodes.
  • EUS-FNA documented metastatic cancer to the left adrenal in all 4 patients with advanced disease.
  • [MeSH-major] Biopsy, Fine-Needle. Carcinoma, Non-Small-Cell Lung / secondary. Esophagoscopy. Lung Neoplasms / pathology. Lymphatic Diseases / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging / methods. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Interventional
  • [MeSH-minor] Aged. Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma / radiography. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma / ultrasonography. Colonic Neoplasms / pathology. Endometrial Neoplasms / pathology. Female. Fluorodeoxyglucose F18. Granuloma / diagnosis. Histiocytosis / complications. Histiocytosis / diagnosis. Histoplasmosis / complications. Histoplasmosis / diagnosis. Humans. Kidney Neoplasms / pathology. Lung Diseases / complications. Lymphoma / pathology. Lymphoma / radiography. Lymphoma / radionuclide imaging. Lymphoma / ultrasonography. Male. Mediastinum. Middle Aged. Predictive Value of Tests. Prospective Studies. Radiopharmaceuticals. Sarcoidosis / complications. Sarcoidosis / diagnosis. Silicosis / complications. Silicosis / diagnosis. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15620955.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Eisen T, Thatcher N, Leyvraz S, Miller WH Jr, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M: Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer; 2009 Apr;64(1):60-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
  • OBJECTIVE: To evaluate the antitumor activity and safety profile of plitidepsin administered as a 1h weekly intravenous (i.v.) infusion of 3.2mg/m(2) to patients with small cell lung cancer (SCLC) who relapsed or progressed after one line of chemotherapy.
  • Toxicity was assessed using National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0.
  • RESULTS: Twenty pretreated SCLC patients (median age, 60 years) with extensive (n = 13) or limited-stage disease (n = 7) received a total of 24 treatment cycles (median, one cycle per patient; range, 1-2).
  • Objective tumor responses were not observed and only one of the 17 evaluable patients had SD.
  • [MeSH-minor] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / secondary. Adult. Aged. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Humans. Infusions, Intravenous. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Salvage Therapy. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18692272.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Depsipeptides; Y76ID234HW / aplidine
  •  go-up   go-down


23. Tibaldi C, Vasile E, Bernardini I, Orlandini C, Andreuccetti M, Falcone A: Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. J Cancer Res Clin Oncol; 2008 Oct;134(10):1143-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model.
  • PURPOSE: We aimed to investigate the prognostic significance of several baseline variables in stage IIIB-IV non-small cell lung cancer to create a model based on independent prognostic factors.
  • Performance status of 2, squamous histology, number of metastatic sites >2, presence of bone, brain, liver and contralateral lung metastases and elevated leukocyte count in peripheral blood were all statistically significant prognostic factors in univariate analyses whereas the other tested variables (sex, stage, age, presence of adrenal gland and skin metastases) were not.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347812.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


24. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J: Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab; 2006 Jul;91(7):2650-5
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.
  • Mean age at diagnosis was 44 +/- 16 yr (range, 11-88 yr).
  • We found that 154 patients (76%) had hypersecreting tumors [mostly cortisol and androgens (47%), cortisol alone (27%), or androgens alone (6%)] and 43 patients (21%) had metastases at diagnosis.
  • Multivariate analysis identified the following independent prognostic factors associated with shorter survival: older age at diagnosis [hazard ratio (HR), 1.03; P < 0.0001], initial MacFarlane extension stages 3 (HR, 4.42; P = 0.005) and 4 (HR, 7.93; P < 0.0001), and cortisol hypersecretion (HR, 3.90; P < 0.0001).
  • CONCLUSION: This study highlights the better prognosis of ACC diagnosed at a noninvasive local stage, the particularly poor prognosis of patients with cortisol-secreting tumors, and the beneficial effect of o,p'DDD therapy in this subgroup of patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / secretion. Hydrocortisone / secretion
  • [MeSH-minor] Adult. Analysis of Variance. Androgens / secretion. Antineoplastic Agents, Hormonal / therapeutic use. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Mitotane / therapeutic use. Neoplasm Staging. Prognosis. Survival Rate

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670169.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


25. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A: Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg; 2006 May;30(5):872-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adrenocortical carcinoma (ACC), a rare and aggressive malignancy, accounts for up to 14% of adrenal incidentalomas.
  • The only chance of cure for ACC is diagnosis at an early stage; therefore, a main indication for adrenalectomy in patients with adrenal incidentaloma has been the potential risk of ACC.
  • Recent studies suggest that this has led to earlier stage of ACC at diagnosis, more curative operations, and better survival.
  • METHODS: We analyzed data on ACC from The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database.
  • The average tumor size was 12 cm (range: 2-36 cm), and only 4.2% were < or = 6 cm.
  • Most (88%) patients had surgical resection of their tumor, and external beam radiotherapy was used in only 12% of patients.
  • Between the time quartiles compared (as well as annually), there was no significant difference at presentation in age at diagnosis, sex, race/ethnicity, tumor size, tumor grade, the frequency of distant metastasis, and overall TNM stage.
  • Low tumor grade, lower stage of ACC, later time quartile, and surgical resection were associated with a lower cause-specific mortality by univariate analysis (P < or = 0.002) and by multivariate analysis (P < or = 0.031).
  • CONCLUSIONS: Although adrenal incidentalomas have become a common indication for adrenalectomy, this has not resulted in patients with ACC being diagnosed earlier or treated at a lower stage of disease at the national level.
  • The most important predictors of survival in these patients are tumor grade, tumor stage, and surgical resection.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. SEER Program. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16680602.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Kim YS, Kim N, Kim SY, Cho KS, Park MJ, Choi SH, Lim SH, Yim JY, Cho KR, Kim CH, Kim DH, Kim SS, Kim JH, Choi BI, Jung HC, Song IS, Shin CS, Cho SH, Oh BH: Extracolonic findings in an asymptomatic screening population undergoing intravenous contrast-enhanced computed tomography colonography. J Gastroenterol Hepatol; 2008 Jul;23(7 Pt 2):e49-57
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • New extracolonic cancer was detected in 0.5% (12/2230), and the majority of them (83.3%) were not metastasized.
  • Computed tomography colonography missed eight potentially important extracolonic findings in eight subjects (0.4%, 8/2230): 0.8-cm early-stage prostatic cancer, six adrenal mass and one intraductal papillary mucinous tumor.
  • CONCLUSION: Intravenous contrast-enhanced CTC could safely detect asymptomatic early-stage extracolonic malignant diseases without an unreasonable number of additional work-ups, thus reducing their morbidity or mortality.
  • [MeSH-minor] Adrenal Glands / radiography. Aged. Aged, 80 and over. Biliary Tract / radiography. Blood Vessels / pathology. Cost-Benefit Analysis. Early Diagnosis. Esophagus / radiography. Female. Humans. Injections, Intravenous. Kidney / radiography. Liver / radiography. Lung / radiography. Male. Medical Records. Middle Aged. Pancreas / radiography. Predictive Value of Tests. Prospective Studies. Stomach / radiography. Time Factors. Urogenital System / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645481.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


27. Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, Frank I, Zincke H, Blute ML: Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma? J Urol; 2005 Oct;174(4 Pt 1):1218-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Perinephric and renal sinus fat invasion are classified as pT3a renal cell carcinoma (RCC) according to the 2002 American Joint Committee on Cancer.
  • MATERIALS AND METHODS: Between 1970 and 2002, 205 patients without direct adrenal invasion underwent nephrectomy for pT3a clear cell RCC.
  • In addition, the risk of death persisted in multivariate analysis after adjusting for regional lymph nodes and distant metastases (RR 1.91, 95% CI 1.26-2.89, p=0.002) and after adjusting for the Mayo Clinic SSIGN (stage, size, grade and necrosis) score (RR 1.90, 95% CI 1.25-2.88, p=0.003).
  • [MeSH-minor] Adipose Tissue / pathology. Adrenal Glands / pathology. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Adv Anat Pathol. 2007 Mar;14(2):63-8 [17471114.001]
  • (PMID = 16145373.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Groussin L, Bonardel G, Silvéra S, Tissier F, Coste J, Abiven G, Libé R, Bienvenu M, Alberini JL, Salenave S, Bouchard P, Bertherat J, Dousset B, Legmann P, Richard B, Foehrenbach H, Bertagna X, Tenenbaum F: 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab; 2009 May;94(5):1713-22
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients.
  • CONTEXT: Most adrenal incidentalomas are nonfunctioning adrenocortical adenomas (ACAs).
  • Adrenocortical carcinomas (ACCs) are rare but should be recognized at an early stage.
  • OBJECTIVE: The objective of the study was to evaluate the usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) to predict malignancy in patients without a previous history of cancer.
  • Using a cutoff value above 1.45 for adrenal to liver maxSUV ratio, the sensitivity and specificity to distinguish ACAs from ACCs were, respectively, 1.00 (95% confidence interval 0.85-1.00) and 0.88 (95% confidence interval 0.75-0.96).
  • An adrenal to liver maxSUV ratio less than 1.45 is highly predictive of a benign lesion.
  • [MeSH-major] Adrenal Cortex Neoplasms / radionuclide imaging. Adrenal Cortex Neoplasms / surgery. Fluorodeoxyglucose F18

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190108.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hormones; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


29. Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, Shariat SF, Isbarn H, Arjane P, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI: External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU Int; 2009 Dec;104(11):1661-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To develop nomograms predicting cancer-specific and all-cause mortality in patients managed with either surgery or no surgery for adrenocortical carcinoma (ACC).
  • The predictors comprised age, gender, race, stage and surgery status.
  • Nomograms based on Cox regression model-derived coefficients were used for predicting the cancer-specific and all-cause mortality, and were tested using area under the receiver operating characteristics (ROC) curve.
  • RESULTS: In cancer-specific analyses, the median survival of patients within the development cohort was 26 months, vs 71 months in the external validation cohort (P < 0.001).
  • Three variables (age, stage and surgical status) were included in the nomograms predicting cancer-specific and all-cause mortality.
  • In the external validation cohort, the nomograms achieved between 72 and 80% accuracy for prediction of cancer-specific or all-cause mortality at 1-5 years after either surgery or diagnosis of ACC for non-surgical patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / mortality. Adrenocortical Carcinoma / mortality. Nomograms

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19493261.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


30. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammer G: Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res; 2009 Jan 15;15(2):668-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using Affymetrix Human Genome U133 Plus 2.0 oligonucleotide arrays, transcriptional profiles were generated for 10 normal adrenal cortices (NC), 22 adrenocortical adenomas (ACA), and 33 ACCs.
  • Cluster analysis of the ACCs revealed two subtypes that reflected tumor proliferation, as measured by mitotic counts and cell cycle genes.
  • Multivariate Cox modeling using stage, mitotic rate, and gene expression data as measured by the first principal component for ACC samples showed that gene expression data contains significant independent prognostic information (P < 0.017).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1039-45 [10514385.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):579-83 [15920519.001]
  • [Cites] Eur J Endocrinol. 2005 Oct;153(4):477-87 [16189167.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6646-56 [16007166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Surgery. 2005 Dec;138(6):1087-94 [16360395.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1043-8 [16921376.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5079-90 [17075127.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):632-41 [17082810.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):600-8 [17234769.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):1-12 [17237261.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):20-47 [16931767.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):175-8 [17427106.001]
  • [Cites] APMIS. 2007 Apr;115(4):381-4 [17504308.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):345-54 [17525483.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):355-63 [17525484.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Oct;4(10):591-602 [17898809.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):425-31 [18281524.001]
  • [Cites] Endocr J. 2008 Mar;55(1):49-55 [18187873.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1442-9 [18198226.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):145-52 [10824999.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1231-8 [11583950.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1170-6 [11889182.001]
  • [Cites] Endocr Pathol. 2001 Winter;12(4):397-406 [11914473.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3467-74 [12107267.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1985-95 [14578198.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):809-17 [15191351.001]
  • [Cites] Horm Metab Res. 2004 Jun;36(6):397-405 [15241731.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4219-23 [8797595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Mol Endocrinol. 1999 Aug;23(1):23-32 [10425444.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]
  • (PMID = 19147773.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA046592-209023; United States / NCI NIH HHS / CA / CA046592-219023; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / CA046592-199023; United States / NCI NIH HHS / CA / P30 CA046592-219023; United States / NCI NIH HHS / CA / P30 CA046592-199023; United States / NCI NIH HHS / CA / P30 CA046592-209023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin E
  • [Other-IDs] NLM/ NIHMS78831; NLM/ PMC2629378
  •  go-up   go-down


31. Fujino M, Shirato H, Onishi H, Kawamura H, Takayama K, Koto M, Onimaru R, Nagata Y, Hiraoka M: Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J; 2006 Jan-Feb;12(1):41-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To find possible risk factors for symptomatic radiation pneumonitis (RP) after stereotactic irradiation (STI) for peripheral non-small cell lung cancer (NSCLC), pre-treatment pulmonary function test and dose volume statistics in patients who developed RP requiring steroid intake were retrospectively compared with statistics of those who did not develop RP.
  • MATERIALS AND METHODS: From 1996 to 2002, 156 patients with Stage I NSCLC received STI at 5 hospitals in Japan.
  • RESULTS: There were no statistical differences in age, sex, tumor size, performance status, forced expiratory volume in 1 sec (FEV1.0%), or percent vital capacity (%VC) between patients medicated with steroids for RP and those who did not have RP and received no steroids.
  • CONCLUSIONS: Pre-treatment pulmonary function test (%VC, FEV1.0%), and dose volume statistics V20, total dose, BED, dose per fraction, peripheral dose) were not predictive of RP requiring steroid intake after STI for stage I NSCLC.
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Radiotherapy Dosage. Respiratory Function Tests. Retrospective Studies. Risk Factors. Stereotaxic Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer J. 2006 Jan-Feb;12(1):19-20 [16613657.001]
  • (PMID = 16613661.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


32. Libè R, Groussin L, Tissier F, Elie C, René-Corail F, Fratticci A, Jullian E, Beck-Peccoz P, Bertagna X, Gicquel C, Bertherat J: Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res; 2007 Feb 1;13(3):844-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor suppressor gene TP53 is located at 17p13.
  • TP53-mutant tumors were significantly larger than wild-type TP53 tumors (median tumor weight: 640 versus 185 g; P=0.02), were associated with a more advanced stage of tumor progression (MacFarlane stage IV; P=0.01), and had a shorter disease-free survival (P=0.03).
  • CONCLUSIONS: The finding that only a minority of adrenocortical tumors with 17p13 LOH had either a VNTR1 LOH or a TP53 mutation indicates that TP53 might not be the only or major tumor suppressor gene at 17p13 involved in adrenocortical cancer progression.
  • We suggest that a genetic instability of the 17p13 region, occurring early in adrenocortical cancer development, involves various genes located in this region.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Chromosomes, Human, Pair 17. Genes, p53. Loss of Heterozygosity. Minisatellite Repeats / genetics. Mutation
  • [MeSH-minor] Adult. Alleles. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Neoplasm / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17289876.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  •  go-up   go-down


33. Tsuchida Y, Miyauchi J, Kuroiwa M, Suzuki N, Sakamoto J, Suzuki M, Shitara T: Histologic survey of neuroblastomas after intensive induction chemotherapy. Pediatr Blood Cancer; 2005 Oct 15;45(5):656-62
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty patients were >12 months of age with stage 3/4 disease, and 4 were <12 months of age but with MYCN-amplified stage 4 diseases.
  • After 3 to 7 cycles (mean, 4.3 cycles) of induction chemotherapy, patients underwent radical surgery of the primary tumor and lymph nodes in all retroperitoneal sections.
  • A single pathologist reviewed all of the specimens, and histologic chemotherapeutic effects were graded as: (+++), <1% viable tumor; (++), 1%-10% viable tumor; (+), 11%-50% viable tumor; (+/-), 51%-90% viable tumor; and (-), >91% viable tumor.
  • Histologically, metastases were found in the contralateral nodes beyond the aorta in 92% of those whose tumor originated on the left, and in 80% of those with tumors occurring on the right.
  • [MeSH-minor] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / pathology. Child. Child, Preschool. Humans. Infant. Lymphatic Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929130.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Ohta S, Lai EW, Morris JC, Bakan DA, Klaunberg B, Cleary S, Powers JF, Tischler AS, Abu-Asab M, Schimel D, Pacak K: MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice. Int J Cancer; 2006 Nov 1;119(9):2236-41
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Successful outcomes for patients with cancer often depend on the early detection of tumor and the prompt initiation of active therapy.
  • Despite major advances in the treatment of many cancers, early-stage lesions often go undetected due to the suboptimal resolution of current anatomical and functional imaging modalities.
  • This limitation also applies to preclinical animal tumor models that are crucial for the evaluation and development of new therapeutic approaches to cancer.
  • Furthermore, we show that in vivo microCT imaging enhanced using a hepatobiliary-specific contrast agent, glyceryl-2-oleyl-1,3-di-7-(3-amino-2,4,6-triiodophenyl)-heptanoate (DHOG), detected tumors as small as 0.35 mm as early as 4 weeks after the injection of the tumor cells.
  • This model may be useful for in vivo studies of tumor biology and for development of new strategies to treat metastatic pheochromocytoma.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] J Neurosci. 1993 Mar;13(3):1280-91 [7680068.001]
  • [Cites] J Med Chem. 1995 Feb 17;38(4):636-46 [7861412.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):765-89 [9735133.001]
  • [Cites] Urology. 1999 Apr;53(4):679-83 [10197840.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):755-64; discussion 764-6 [10363888.001]
  • [Cites] Mol Imaging. 2004 Jul;3(3):149-58 [15530250.001]
  • [Cites] Cell Tissue Res. 2005 Dec;322(3):443-53 [16047163.001]
  • [Cites] Mol Psychiatry. 2002;7(9):967-74 [12399950.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):320-7 [12600234.001]
  • [Cites] Acad Radiol. 2002 May;9 Suppl 1:S200-4 [12019869.001]
  • [Cites] Invest Radiol. 2000 Mar;35(3):158-69 [10719825.001]
  • [Cites] Radiology. 2000 Sep;216(3):865-71 [10966724.001]
  • [Cites] Cell Tissue Res. 2000 Dec;302(3):309-20 [11151443.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):315-29 [11182843.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2968-73 [11306475.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):94-8 [11310206.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1999-2008 [11344198.001]
  • [Cites] Am J Ther. 2001 Sep-Oct;8(5):359-65 [11550077.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):883-95 [15168351.001]
  • [Cites] Surgery. 2004 Aug;136(2):183-9 [15300178.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5632-42 [15313901.001]
  • [Cites] J Surg Res. 2004 Jun 1;119(1):41-5 [15126080.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):81-91 [12746566.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):539-53 [12920154.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] Science. 2003 Dec 12;302(5652):1880-2 [14671264.001]
  • (PMID = 16841334.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS037685; United States / Intramural NIH HHS / / Z99 CA999999; United States / NINDS NIH HHS / NS / R01 NS 37685
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ NIHMS43416; NLM/ PMC2288741
  •  go-up   go-down


35. Khorram-Manesh A, Ahlman H, Nilsson O, Friberg P, Odén A, Stenström G, Hansson G, Stenquist O, Wängberg B, Tisell LE, Jansson S: Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med; 2005 Jul;258(1):55-66
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients with sporadic disease died of malignant PC and six with hereditary disease of associated neuroectodermal tumours.
  • At diagnosis 85% of the patients were hypertensive; one year after surgery more than half were still hypertensive.
  • Death of malignant PC/PG was unusual, but the patients as a group had an increased risk of death.
  • This strategy would also be helpful in diagnosing cardiovascular disease at an early stage.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Pheochromocytoma / surgery
  • [MeSH-minor] Adrenal Medulla / pathology. Adult. Aged. Blood Pressure / physiology. Female. Humans. Hyperplasia. Hypertension / complications. Male. Middle Aged. Neoplasm Invasiveness. Paraganglioma / mortality. Paraganglioma / pathology. Paraganglioma / surgery. Postoperative Period. Preoperative Care / methods. Receptors, Adrenergic, alpha / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953133.001).
  • [ISSN] 0954-6820
  • [Journal-full-title] Journal of internal medicine
  • [ISO-abbreviation] J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Adrenergic, alpha
  •  go-up   go-down


36. Wu XR, Zhu MH, Zhang ZD: [Expression of KAI1/CD82 in neuroblastoma and its correlation to prognosis]. Ai Zheng; 2005 Jul;24(7):885-9
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: KAI1/CD82 was recently detected as a tumor metastasis suppressor gene.
  • Its expression was negatively correlated to clinical stage of neuroblastoma (P=0.003).
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Antigens, CD82 / metabolism. Ganglioneuroblastoma / metabolism. Neuroblastoma / metabolism. Peritoneal Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Lymphatic Metastasis. Lymphatic Vessels / metabolism. Male. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / pathology. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004821.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD82; 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Leboulleux S, Deandreis D, Al Ghuzlan A, Aupérin A, Goéré D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E: Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol; 2010 Jun;162(6):1147-53
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Peritoneal carcinomatosis (PC) is a rare site of distant metastases in patients with adrenocortical cancer (ACC).
  • Mean tumor size was 132 mm.
  • Patients had stage I disease in 2 cases, stage II disease in 32 cases, stage III disease in 7 cases, stage IV disease in 21 cases, and unknown stage disease in 2 cases.
  • It was present at initial diagnosis in three cases and occurred during follow-up in 15 cases.
  • Neither tumor size, stage, functional status, completeness of surgery, nor plasma level of op'DDD was associated with the occurrence of PC.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348273.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. McNutt DM, Holdsworth MT, Wong C, Hanrahan JD, Winter SS: Rasburicase for the management of tumor lysis syndrome in neonates. Ann Pharmacother; 2006 Jul-Aug;40(7-8):1445-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rasburicase for the management of tumor lysis syndrome in neonates.
  • OBJECTIVE: To describe the management of tumor lysis syndrome (TLS) with rasburicase in 2 patients who presented with cancer within the first month of life and compare and contrast both cases with respect to their underlying renal physiology, management, and eventual outcome.
  • One patient was a 21-day-old infant who received 2 days of induction chemotherapy for the treatment of congenital Stage IV-S neuroblastoma.
  • While rasburicase has the potential to provide a rapid reversal of TLS in this patient population, when TLS is complicated by pre-existing acute renal failure, additional interventions and alternative anti-tumor strategies may be necessary for a successful outcome.
  • [MeSH-major] Tumor Lysis Syndrome / drug therapy. Urate Oxidase / therapeutic use
  • [MeSH-minor] Adrenal Gland Neoplasms / blood. Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / congenital. Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Female. Humans. Infant, Newborn. Male. Neuroblastoma / blood. Neuroblastoma / complications. Neuroblastoma / congenital. Neuroblastoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Uric Acid / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868218.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 268B43MJ25 / Uric Acid; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase
  •  go-up   go-down


39. Goel MC, Mohammadi Y, Sethi AS, Brown JA, Sundaram CP: Pathologic upstaging after laparoscopic radical nephrectomy. J Endourol; 2008 Oct;22(10):2257-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Accurate tumor staging in renal cancer is critical for prognostic projections, follow-up schedules, clinical trials and potential systemic therapies.
  • PATIENTS AND METHODS: A retrospective review of patients undergoing LRN for renal cell cancer was performed.
  • Histopathology reports were studied in to determine the p-stage.
  • RESULTS: One hundred twenty three patients qualified for the study; mean age was 62.14+/-13.6 years, M:F ratio was 60:63 and mean tumor size of 5.3+/-2.0 cm.
  • Clinical versus pathologic T stage distribution was T1a=41:37, T1b=43:31, T2=25:12, T3a=11:31, T3b=3:10 and T4=0:2.
  • Upstaging was due to change in tumor size in 12, renal sinus fat involvement in 8, renal or adrenal vein involvement in 14, focal perirenal fat involvement in 6, and focal renal capsule penetration in 4 patients.
  • Mean tumor size was 5.3+/-2 cms at clinical, and 5.0+/-2.6 cms at pathology staging (P=NS).
  • 5 patients had LN metastasis detected with tumor size of 5.5, 5.6, 6.8, and 7.2 cms in diameter, and one patient with LN metastasis was T1a stage (3.2 cm).
  • Renal vein/inferior venal cava/adrenal vein was involved in 14 patients, adrenal was involved in 21 patients and renal sinus was involved in 19/123 patients.
  • CONCLUSIONS: Pathologic upstaging of malignant renal neoplasms occurred in about 31% of patients following LRN.
  • Down staging was less common and mean tumor size does not significantly change.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937590.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Dubois SG, London WB, Zhang Y, Matthay KK, Monclair T, Ambros PF, Cohn SL, Pearson A, Diller L: Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer; 2008 Nov;51(5):589-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project.
  • BACKGROUND: Neuroblastoma is the most common extracranial pediatric solid cancer.
  • We aimed to describe the incidence, clinical characteristics, and outcome of patients with lung metastasis at initial diagnosis using a large international database.
  • PROCEDURE: The subset of patients from the International Neuroblastoma Risk Group database with INSS stage 4 neuroblastoma and known data regarding lung metastasis at diagnosis was selected for analysis.
  • Cox proportional hazards methods were used to determine the independent prognostic value of lung metastasis at diagnosis.
  • RESULTS: Of the 2,808 patients with INSS stage 4 neuroblastoma diagnosed between 1990 and 2002, 100 patients (3.6%) were reported to have lung metastasis at diagnosis.
  • Lung metastasis was more common among patients with MYCN amplified tumors, adrenal primary tumors, or elevated lactate dehydrogenase (LDH) levels (P < 0.02 in each case).
  • CONCLUSIONS: Lung metastasis at initial diagnosis of neuroblastoma is associated with MYCN amplification and elevated LDH levels.
  • Although lung metastasis at diagnosis was not independently predictive of outcome in this analysis, it remains a useful prognostic marker of unfavorable outcome.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Cancer. 1986 Dec 1;58(11):2501-11 [3021319.001]
  • [Cites] N Engl J Med. 1985 Oct 31;313(18):1111-6 [4047115.001]
  • [Cites] Am J Clin Oncol. 1992 Aug;15(4):295-303 [1514525.001]
  • [Cites] J Pediatr Surg. 1995 Feb;30(2):296-302; discussion 302-3 [7738754.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):429-32 [9143388.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):275-81 [9602261.001]
  • [Cites] J Magn Reson Imaging. 1999 Apr;9(4):621-3 [10232523.001]
  • [Cites] N Engl J Med. 1999 Jun 24;340(25):1954-61 [10379019.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181-9 [10363850.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2856-7 [15837999.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6459-65 [16116153.001]
  • [Cites] N Engl J Med. 2005 Nov 24;353(21):2243-53 [16306521.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):755-9 [11222220.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):397-400 [12142791.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2011-8 [12743156.001]
  • [Cites] AJR Am J Roentgenol. 1982 Jan;138(1):75-8 [6976716.001]
  • [Cites] Cancer. 1983 Sep 1;52(5):915-25 [6871832.001]
  • [Cites] J Natl Cancer Inst. 1984 Aug;73(2):405-16 [6589432.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2843-8 [3986811.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12):1874-81 [3199170.001]
  • (PMID = 18649370.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098543-07; United States / NCI NIH HHS / CA / U10 CA098543-07
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; EC 1.1.1.27 / L-Lactate Dehydrogenase
  • [Other-IDs] NLM/ NIHMS123413; NLM/ PMC2746936
  •  go-up   go-down


41. Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ: Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol; 2009 Aug;33(8):1125-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
  • Risk-reducing salpingo-oophorectomy (RRSO) is an effective prophylactic procedure for women with mutations in BRCA1 or BRCA2 genes, both of which confer an increased lifetime risk for ovarian, tubal, peritoneal, and breast cancer.
  • In addition to lowering this risk, RRSO also offers the opportunity to detect occult early-stage fallopian tube or ovarian carcinoma.
  • The differential diagnosis of occult tubal/ovarian cancer includes a spectrum of benign tubal and ovarian alterations and also occult metastatic breast cancer, although only rare cases of the latter have been reported in RRSO.
  • Neoadjuvant breast cancer chemotherapy may contribute to diagnostic difficulty due to treatment-induced cytologic alterations.
  • With the aim of elucidating features which may help with differential diagnosis, this study reports the incidence and pathologic features of benign ovarian alterations, benign ovarian tumors, and occult primary and metastatic malignancies in prophylactic oophorectomies from 108 women with a BRCA mutation and from 35 women with other strong risk factors for hereditary breast/ovarian carcinoma.
  • We direct particular emphasis on morphologic features of primary ovarian lesions that may mimic occult metastatic breast cancer.
  • We also evaluate histologic alterations due to neoadjuvant breast cancer chemotherapy in the ovary and fallopian tube of patients who received such treatment immediately preceding RRSO.
  • Comparison is made to ovarian metastases of breast cancer in our hospital-based population of breast cancer patients, none of whom underwent RRSO.
  • Overall, 69% of RRSO patients had a personal history of breast cancer.
  • Neoadjuvant breast cancer chemotherapy was administered in 15%.
  • Ovarian metastasis of breast cancer occurred in 1 (1%) BRCA patient undergoing RRSO and in up to a similar proportion (0.8%) of the hospital-based population of breast cancer patients.
  • In contrast, ovarian metastases in the non-RRSO population were all clinically detected, bilateral, large, and exhibited well-developed malignant cytologic features.
  • The main morphologic mimics of metastasis with superimposed chemotherapy-induced alterations in RRSO were stromal hyperthecosis (n=8), nodular hyperthecosis (n=2), adrenal rests (n=3), hilus cell nodules (n=43), and hilus cell hyperplasia (n=4).
  • Occult primary ovarian carcinoma was reliably distinguished from ovarian metastases of breast cancer by WT-1+, p53+, mammaglobin-, GCDPF-immunoprofile.
  • These results demonstrate that evaluation of RRSO specimens requires awareness of a spectrum of ovarian lesions which may mimic occult primary or metastatic carcinoma; awareness of the masquerading effects of neoadjuvant chemotherapy; and awareness of the potential morphologic differences between occult metastatic breast cancer in RRSO and non-RRSO specimens.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Genetic Predisposition to Disease. Humans. Mutation. Neoplasms, Multiple Primary / genetics. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / prevention & control. Ovariectomy. Ovary / drug effects. Ovary / pathology. Risk Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19440148.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


42. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med; 2007 Jun 7;356(23):2372-80
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adrenocortical carcinoma is a rare neoplasm characterized by a high risk of recurrence after radical resection.
  • METHODS: We performed a retrospective analysis involving 177 patients with adrenocortical cancer who had undergone radical surgery at 8 centers in Italy and 47 centers in Germany between 1985 and 2005.
  • RESULTS: Baseline features in the mitotane group and the control group from Italy were similar; the German patients were significantly older (P=0.03) and had more stage I or II adrenocortical carcinomas (P=0.02) than did patients in the mitotane group.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Multivariate Analysis. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Retrospective Studies. Survival Analysis


43. Shen XC, Gu CX, Qiu YQ, Du CJ, Fu YB, Wu JJ: Estrogen receptor expression in adrenocortical carcinoma. J Zhejiang Univ Sci B; 2009 Jan;10(1):1-6
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare but highly malignant tumor, and its diagnosis is mostly delayed and prognosis is poor.
  • We report estrogen receptor (ER) expression in this tumor and our clinical experiences with 17 ACC cases.
  • Immunohistochemistry was used to detect ER expression in tumor samples from the 17 patients.
  • RESULTS: At the time of diagnosis, 4 tumors were classified as Stage I, 4 as Stage II, 3 as Stage III, and 6 as Stage IV.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenal Cortex Neoplasms / mortality. Adrenocortical Carcinoma / metabolism. Adrenocortical Carcinoma / mortality. Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Curr Urol Rep. 2004 Feb;5(1):65-72 [14733841.001]
  • [Cites] J Urol. 1978 Dec;120(6):660-5 [731800.001]
  • [Cites] Cancer Res. 1983 Aug;43(8):3583-5 [6861130.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Endocr Rev. 1987 Feb;8(1):29-43 [3549276.001]
  • [Cites] Cancer Res. 1989 Apr 1;49(7):1882-4 [2924327.001]
  • [Cites] Am J Clin Pathol. 1992 Jan;97(1):73-83 [1728867.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):791-805 [9735134.001]
  • [Cites] World J Urol. 1999 Feb;17(1):26-34 [10096148.001]
  • [Cites] Ann R Coll Surg Engl. 1958 Sep;23(3):155-86 [13571886.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):667-80 [16172199.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • (PMID = 19198016.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC2613956
  •  go-up   go-down


44. Landfried K, Bataille F, Rogler G, Brenmoehl J, Kosovac K, Wolff D, Hilgendorf I, Hahn J, Edinger M, Hoffmann P, Obermeier F, Schoelmerich J, Andreesen R, Holler E: Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. Clin Exp Immunol; 2010 Jan;159(1):87-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intestinal GVHD was associated with a stage-dependent decrease in CD4 T cell infiltrates and an increase in CD8 T cells in the lamina propria; CD8 infiltrates correlated with extent of apoptosis and consecutive epithelial proliferation.
  • [MeSH-minor] Adrenal Cortex Hormones / pharmacology. Adrenal Cortex Hormones / therapeutic use. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / pathology. Cell Count. Forkhead Transcription Factors / metabolism. Humans. Immunosuppressive Agents / pharmacology. Immunosuppressive Agents / therapeutic use. Intestinal Mucosa / pathology. Middle Aged. Mucous Membrane / pathology. Neutrophils / pathology. Transplantation, Homologous / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1991 Apr;7(4):297-301 [2070136.001]
  • [Cites] Transplantation. 1991 Dec;52(6):1029-36 [1836284.001]
  • [Cites] Am J Clin Pathol. 1995 Jun;103(6):690-5 [7785652.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1717-23 [16278306.001]
  • [Cites] Blood. 2006 May 15;107(10):4189-93 [16424393.001]
  • [Cites] Inflamm Bowel Dis. 2006 Jul;12(7):598-605 [16804397.001]
  • [Cites] J Exp Med. 2006 Aug 7;203(8):2021-31 [16880259.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1627-40 [17499605.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):7032-41 [17513752.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1757-64 [17620361.001]
  • [Cites] Immunity. 2007 Oct;27(4):660-9 [17919942.001]
  • [Cites] Transplant Proc. 2007 Dec;39(10):3065-7 [18089323.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):67-74 [18158963.001]
  • [Cites] Inflamm Bowel Dis. 2008 Feb;14(2):186-94 [17941075.001]
  • [Cites] Blood. 2008 Sep 1;112(5):2101-10 [18596226.001]
  • [Cites] Blood. 2009 Jan 22;113(4):945-52 [18931341.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1365-74 [18957685.001]
  • [Cites] Adv Immunol. 2009;101:1-25 [19231591.001]
  • [Cites] J Exp Med. 2009 Sep 28;206(10):2101-10 [19737867.001]
  • [Cites] Nature. 2001 May 31;411(6837):603-6 [11385577.001]
  • [Cites] BMC Gastroenterol. 2003 Mar 27;3:5 [12697049.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4365-7 [14962899.001]
  • [Cites] Blood. 2004 Aug 1;104(3):889-94 [15090455.001]
  • [Cites] Gut. 2004 Nov;53(11):1658-64 [15479689.001]
  • [Cites] J Natl Cancer Inst. 1974 Feb;52(2):401-4 [4150164.001]
  • [Cites] Am J Surg Pathol. 1979 Aug;3(4):291-9 [44107.001]
  • (PMID = 19912254.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Immunosuppressive Agents; 0 / NOD2 protein, human; 0 / Nod2 Signaling Adaptor Protein
  • [Other-IDs] NLM/ PMC2802698
  •  go-up   go-down


45. Cheng Y, Li J, Martinka M, Li G: The expression of NAD(P)H:quinone oxidoreductase 1 is increased along with NF-kappaB p105/p50 in human cutaneous melanomas. Oncol Rep; 2010 Apr;23(4):973-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies demonstrated that NQO1 is overexpressed in many types of tumors, including the lung, ovary, adrenal gland, thyroid, liver, colon, breast, and pancreas.
  • Our results also revealed that the increase of NQO1 was not associated with patient age, tumor thickness, ulceration, tumor site, American Joint Committee on Cancer (AJCC) stage, and 5-year patient survival.
  • Furthermore, NQO1 expression level was significantly higher in superficial spreading melanomas compared with other tumor subtypes (P=0.020, chi2 test).
  • Our findings suggest that NQO1 may play an important role in the initiation stage of melanoma development.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Sex Factors. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204281.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP-84559; Canada / Canadian Institutes of Health Research / / MOP-93810
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / NF-kappa B p50 Subunit; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human
  •  go-up   go-down


46. Lao XM, Chen DY, Zhang YQ, Xiang J, Guo RP, Lin XJ, Li JQ: Primary carcinosarcoma of the liver: clinicopathologic features of 5 cases and a review of the literature. Am J Surg Pathol; 2007 Jun;31(6):817-26
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Satellite nodules, portal vein tumor thrombi, direct invasion into local tissues (right diaphragm, right adrenal gland, and gastric wall) as well as metastatic foci in lungs and abdominal lymph nodes were identified.
  • Confirmed by IHC studies, the sarcomatous elements in different cases included rhabdomyosarcomas, malignant fibrous histiocytomas, fibrosarcoma, and poorly differentiated spindle cells without distinctive differentiation.
  • Furthermore, the sarcomatous elements in these 5 neoplasms stained negative for all the epithelial markers we applied for IHC staining, which support the pathologic diagnosis of carcinosarcoma rather than sarcomatoid carcinoma.
  • Radical resection of early stage hepatic carcinosarcoma may contribute to a relatively optimistic prognosis.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527068.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Bodendorf MO, Haas V, Laberke HG, Blumenstock G, Wex P, Graeter T: Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. Lung Cancer; 2009 Apr;64(1):71-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All had been treated by potentially curative surgical resection of the primary tumor and systematic lymphadenectomy.
  • In all cases, lymphatic metastatic spread was at its earliest stage and only one regional lymph node was involved, 27.0+/-8.9 nodes per patient being examined histologically.
  • 62.5% were at stage IIB, 25.9% at stage IIIA, and 9.8% at stage IIA.
  • Local recurrence occurred in 10.7% of the patients, distant metastasis in 24.1%, and both forms of tumor progression simultaneously in a further 7.1%.
  • Thus 31.2% of the patients developed distant metastases by hematogenous spread (to the brain, bones, lung, adrenal, and liver, in descending order of frequency), mostly within two years of surgery.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790545.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


48. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, Hiramatsu A, Kodama H, Takahashi S, Chayama K: Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol; 2007 Jan 21;13(3):414-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: After the diagnosis of HCC, all 995 consecutive HCC patients were followed up at regular intervals and 151 (15.2%) patients were found to have extrahepatic metastases at the initial diagnosis of primary HCC or developed such tumors during the follow-up period.
  • RESULTS: The most frequent site of extrahepatic metastases was the lungs (47%), followed by lymph nodes (45%), bones (37%), and adrenal glands (12%).
  • The cumulative survival rates after the initial diagnosis of extrahepatic metastases at 6, 12, 24, and 36 mo were 44.1%, 21.7%, 14.2%, 7.1%, respectively.
  • Although most of HCC patients with extrahepatic metastases should undergo treatment for the primary HCC mainly, treatment of extrahepatic metastases in selected HCC patients who have good hepatic reserve, intrahepatic tumor stage (T0-T2), and are free of portal venous invasion may improve survival.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cause of Death. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / mortality. Liver Neoplasms / therapy. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / therapy. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):1049-52 [10370665.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1198-200 [9752858.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):61-7 [15709088.001]
  • [Cites] Cardiovasc Intervent Radiol. 2005 Sep-Oct;28(5):578-83 [16059766.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7 [16246200.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1067-76 [15913915.001]
  • [Cites] Radiology. 2000 Sep;216(3):698-703 [10966697.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):63-70 [11420484.001]
  • [Cites] Dig Surg. 2001;18(4):294-7 [11528139.001]
  • [Cites] J Gastroenterol. 2002;37(7):571-4 [12162418.001]
  • [Cites] Surg Today. 2002;32(12):1035-41 [12541019.001]
  • [Cites] Am Surg. 2003 Oct;69(10):879-85 [14570367.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Cancer. 1985 May 1;55(9):1991-4 [2983871.001]
  • [Cites] Clin Nucl Med. 1992 Feb;17(2):99-100 [1314154.001]
  • [Cites] Int J Dermatol. 1992 Apr;31(4):273-6 [1321795.001]
  • [Cites] Gastroenterol Jpn. 1993 Apr;28(2):312-6 [8387439.001]
  • [Cites] Hepatogastroenterology. 1993 Aug;40(4):316-9 [7691699.001]
  • [Cites] Clin Orthop Relat Res. 1994 Jun;(303):237-41 [8194240.001]
  • [Cites] Abdom Imaging. 1994 Jul-Aug;19(4):309-12 [8075551.001]
  • [Cites] Br J Surg. 1994 Jul;81(7):1019-21 [7922051.001]
  • [Cites] J Am Soc Echocardiogr. 1994 Sep-Oct;7(5):547-9 [7986554.001]
  • [Cites] Chin Med J (Engl). 1995 Aug;108(8):568-70 [7587484.001]
  • [Cites] World J Gastroenterol. 2006 Mar 28;12(12):1969-71 [16610010.001]
  • [Cites] Hepatogastroenterology. 1997 Jan-Feb;44(13):251-7 [9058154.001]
  • [Cites] Jpn J Clin Oncol. 2004 Dec;34(12):733-9 [15640504.001]
  • (PMID = 17230611.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4065897
  •  go-up   go-down


49. Hirano H, Yoshida T, Sakamoto T, Yoshimura H, Fukuoka M, Tachibana S, Saito H, Ohkubo E, Nakasho K, Nishigami T: Pulmonary pleomorphic carcinoma producing hCG. Pathol Int; 2007 Oct;57(10):698-702
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 80-year-old woman with a pleomorphic carcinoma (PC) producing hCG was admitted to Nippon Steel Hirohata Hospital because of an abnormal shadow on CT seen during a follow-up examination after surgery for breast cancer.
  • Macroscopically the tumor was a 4.8 x 4.0 cm well-circumscribed grayish-white mass.
  • On histology the tumor consisted mostly of intermingled spindle and polygonal cells, while evidence of poorly differentiated adenocarcinoma was seen in a few areas.
  • A diagnosis of PC was made due to hCG expression in approximately 20% of the spindle and polygonal cells on immunohistology.
  • Six months after the operation metastasis to the liver and adrenal gland was seen on CT.
  • The patient died due to metastases 1 year after the operation, even though the patient had been at stage 1B at the time of the operation and appropriate chemotherapy had been given.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinosarcoma / metabolism. Chorionic Gonadotropin / metabolism. Lung Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803660.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin
  •  go-up   go-down


50. Bedke J, Buse S, Pritsch M, Macher-Goeppinger S, Schirmacher P, Haferkamp A, Hohenfellner M: Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. BJU Int; 2009 May;103(10):1349-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the influence of perinephric (PN) and renal sinus (RS) fat infiltration on cancer-specific survival beyond other prognostic factors, as the Tumour-Node-Metastasis (TNM) classification system defines stage T3a renal cell carcinoma (RCC) as infiltration of perirenal fat and/or direct infiltration of the adrenal gland.
  • In this group of RS + PN fat infiltration the 5-year cancer-specific survival was 31%.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19076147.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement